Affordable Access

Inhibition of HIV type 1 Tat-mediated trans-activation by oncostatin M in HLtat cells.

Authors
  • Esté, J A
  • Witvrouw, M
  • Tu, J
  • Desmyter, J
  • De Clercq, E
  • Vandamme, A M
Type
Published Article
Journal
AIDS research and human retroviruses
Publication Date
Nov 01, 1995
Volume
11
Issue
11
Pages
1355–1358
Identifiers
PMID: 8573392
Source
Medline
License
Unknown

Abstract

We have tested the effect of oncostatin M (OSM) on the Tat-mediated trans-activation in a HeLa cell line (HLtat) expressing Tat, using a transfection assay with the LacZ gene under the control of the HIV-1 LTR. Oncostatin M reduced the LacZ expression by 50% at a concentration of 9.5 ng/ml (IC50), which was far below the 50% cytotoxic concentration (CC50 > 400 ng/ml). Although HLtat cells may represent an interesting model for the study of the signal transduction pathway of OSM, this cytokine did not inhibit the tumor necrosis factor (TNF)-dependent activation of the HIV LTR in Molt pNAZ cells or the Tat-mediated trans-activation in HeLa, HeLa-CD4, Hep-II, COS-7, or Jurkat-tat cells. Likewise, OSM did not show any anti-HIV-1 activity in the MT4 cell/MTT assay. Our findings with OSM indicate that, for the screening of HIV Tat inhibitors, care must be taken in selecting a system that not only emulates HIV Tat trans-activation, but is also representative for in vivo-infected cells.

Report this publication

Statistics

Seen <100 times